
    
      Study Design:

      This is a multi-center, randomized, double-blind, placebo-controlled, 3-period crossover
      study of rhC1INH in prophylaxis of angioedema attacks in patients with HAE.

      Medical screening (clinical and laboratory parameters) will be performed and patient medical
      history specific to HAE attacks will be collected to assess eligibility. Each patient will
      receive three 4 week periods of treatment twice weekly.
    
  